Laprosep

Latanoprost, the active ingredient in Laprosep, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for open‑angle glaucoma and ocular hypertension in adult patients. GNH USA supplies Laprosep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Laprosep belongs to the prostaglandin analog class and is used to manage conditions that involve elevated intraocular pressure. - Open‑angle glaucoma: reduces intraocular pressure to slow optic nerve damage. - Ocular hypertension: lowers pressure to prevent progression to glaucoma. - Normal‑tension glaucoma: helps maintain pressure within a safe range to protect visual fields.

Latanoprost may cause ocular and systemic reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness: transient hyperemia of the conjunctiva. - Increased eyelash growth: longer, thicker lashes on the treated eye. - Iris darkening: gradual brownish pigmentation change. - Eye irritation or foreign‑body sensation: mild discomfort after instillation.

Serious or Rare Side Effects: - Elevated intraocular pressure: paradoxical increase requiring medical attention. - Uveitis: inflammation of the uveal tract. - Macular edema: fluid accumulation in the retina, potentially affecting vision. - Severe allergic reaction: swelling, itching, or rash around the eye.

Before using Laprosep, consider the following safety measures. - Pregnancy: consult a healthcare provider, as safety data are limited. - Breastfeeding: unknown safety; discuss risks with a physician. - Active ocular inflammation: avoid use until inflammation resolves. - Monitoring: regular intraocular pressure checks are essential to assess efficacy. - Store at room temperature: keep the bottle tightly closed, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may diminish latanoprost efficacy. - Concurrent prostaglandin analogs: additive effects can increase risk of side effects.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: combined use may produce excessive pressure reduction. - Systemic carbonic anhydrase inhibitors: may enhance intraocular pressure lowering. - Anticholinergic eye preparations: could affect ocular surface tolerance.